4-(己氧基)-1-丁醇 | 4541-13-3

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 4-(己氧基)-1-丁醇
• 英文名称: 4-n-Hexoxy-1-butanol
• 英文别名: 4-n-Hexyl-1-butanol；4-hexyloxy-butan-1-ol；4-(Hexyloxy)-1-butanol；4-hexoxybutan-1-ol
• CAS: 4541-13-3
• 化学式: C₁₀H₂₂O₂
• 分子量: 174.283
• InChiKey: NTRCGACLCLJKBB-UHFFFAOYSA-N

物化性质

• 沸点：
  253.4±8.0 °C(Predicted)
• 密度：
  0.882±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  12
• 可旋转键数：
  9
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  29.5
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2909499000

反应信息

• 作为反应物：
  描述：

  4-(己氧基)-1-丁醇 在 sodium 、 三溴化磷 、 potassium hydroxide 作用下， 以 乙醇 为溶剂， 反应 28.0h， 生成 6-Hexoxyhexanoic acid
  参考文献：
  名称：

  JP5760218

  摘要：

  公开号：
• 作为产物：
  描述：

  在 palladium on activated charcoal 氢气 作用下， 以 乙醇 为溶剂， 生成 4-(己氧基)-1-丁醇
  参考文献：
  名称：

  Synthesis and antiproliferative activity of alkylphosphocholines

  摘要：

  Alkylphosphocholines (APC) with one or more methylene groups in the alkyl chain replaced by oxygen atoms or carbonyl groups, or both have been assembled modularly using w-diols as central building blocks. Out of 25 new compounds of this kind, I I were evaluated for their antiproliferative activity on four cell lines and compared with miltefosine to evaluate their hemolytic activity (HA); and cytotoxicity on non-tumoral cells (MT2), used as markers of adverse effects. Compound 13 was more active on cancer cell lines than on non-tumoral cells and the data were similar for MTT and thymidine incorporation assays. It had less HA than miltefosine, Compound 13 could therefore be a candidate for the preparation of compounds with higher cytotoxicity on cancer cells and lower general toxicity. (C) 2003 Elsevier Ireland Ltd. All rights reserved.

  DOI：

  10.1016/j.chemphyslip.2003.08.002

文献信息

• DIHYDROPYRIDAZINE-3,5-DIONE DERIVATIVE AND PHARMACEUTICALS CONTAINING THE SAME
  申请人：CHUGAI SEIYAKU KABUSHIKI KAISHA

  公开号：US20160002251A1

  公开（公告）日：2016-01-07

  The present invention provides a dihydropyridazine-3,5-dione derivative or a salt thereof, or a solvate of the compound or the salt, a pharmaceutical drug, a pharmaceutical composition, a sodium-dependent phosphate transporter inhibitor, and a preventive and/or therapeutic agent for hyperphosphatemia, secondary hyperparathyroidism, chronic renal failure, chronic kidney disease, and arteriosclerosis associated with vascular calcification comprising the compound as an active ingredient, and a method for prevention and/or treatment.

  本发明提供了一种二氢吡啶嗪-3,5-二酮衍生物或其盐，或化合物或盐的溶剂化合物，一种药物，一种药物组合物，一种钠依赖性磷酸盐转运体抑制剂，以及作为活性成分的化合物的高磷血症、继发性甲状旁腺功能亢进症、慢性肾功能衰竭、慢性肾病和与血管钙化相关的动脉硬化的预防和/或治疗剂，以及预防和/或治疗的方法。
• Omega-hydrofluoroalkyl ethers, precursor carboxylic acids and derivatives thereof, and their preparation and application
  申请人：MINNESOTA MINING AND MANUFACTURING COMPANY

  公开号：EP1170275A3

  公开（公告）日：2004-04-14

  Normally liquid, omega-hydrofluoroalkyl ether compounds (and selected mixtures thereof) have a saturated perfluoroaliphatic chain of carbon atoms interrupted by one or more ether oxygen atoms. The compounds can be prepare, e.g. by decarboxylation of the corresponding fluoroalkyl ether carboxylic acids and are useful, e.g., in cleaning and drying applications.

  通常是液体的ω-氢氟烷基醚化合物（及其选定的混合物）具有由一个或多个醚氧原子中断的饱和全氟脂肪链的碳原子。这些化合物可以通过相应的氟烷基醚羧酸的脱羧反应制备，例如在清洁和干燥应用中很有用。
• SUBSTITUTED SPIROPYRIDO[1,2-a]PYRAZINE DERIVATIVE AND PHARMACEUTICAL USE OF SAME AS HIV INTEGRASE INHIBITOR
  申请人：JAPAN TOBACCO INC.

  公开号：US20140221378A1

  公开（公告）日：2014-08-07

  Provided is a substituted spiropyrido[1,2-a]pyrazine derivative or a pharmaceutically acceptable salt thereof, which is useful as an anti-HIV agent. The present invention relates to a compound represented by the following formula [I] or [II] or a pharmaceutically acceptable salt thereof: wherein each symbol is as defined in the specification.

  提供了一种替代的螺环吡啶并[1,2-a]吡嗪衍生物或其药用盐，其作为一种抗HIV药物。本发明涉及以下式[I]或[II]所表示的化合物或其药用盐： 其中每个符号如规范中定义的那样。
• 1,3,4,8-Tetrahydro-2H-Pyrido[1,2-a]Pyradine Derivatives and Use Thereof as HIV Integrase Inhibitor
  申请人：MIYAZAKI Susumu

  公开号：US20120108564A1

  公开（公告）日：2012-05-03

  [Problem] Provided is a novel 1,3,4,8-tetrahydro-2H-pyrido[1,2-a]pyrazine derivative or a pharmaceutically acceptable salt thereof, or a solvate thereof, which is useful as an anti-HIV agent. [Solving Means] The present invention provides a compound represented by the following formula [I] wherein each symbol is as defined in the specification, or a pharmaceutically acceptable salt thereof, or a solvate thereof.

  [问题] 提供了一种新颖的1,3,4,8-四氢-2H-吡啶并[1,2-a]吡嗪衍生物或其药学上可接受的盐，或其溶剂合物，该物质作为抗HIV药物具有应用价值。[解决方案] 本发明提供了一种由以下通式[I]表示的化合物，其中各个符号的定义如说明书中所述，或其药学上可接受的盐，或其溶剂合物。
• [EN] PROCESS FOR PRODUCING LOW VOC COALESCING AIDS<br/>[FR] PROCÉDÉ DE PRODUCTION D'AGENTS DE COALESCENCE À FAIBLE TENEUR EN COV
  申请人：DOW GLOBAL TECHNOLOGIES LLC

  公开号：WO2015200088A1

  公开（公告）日：2015-12-30

  A process comprising reacting a mono- or di-carboxylic acid and/or acid anhydride with a glycol ether in the presence of phosphoric acid to produce a glycol ether ester product having low color and low VOC content.

  一种包括在磷酸存在下，将单羧酸或二羧酸及/或酸酐与乙二醇醚反应以生产具有低色度和低VOC含量的乙二醇醚酯产品的过程。